INBRX-109 clinical trials
INBRX-109 is named as an intervention in 2 current clinical trials in our UK, USA, France, Spain, Italy, Netherlands, Ireland, Germany and Australia registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Inhibrx Biosciences, Inc. The most-studied condition is Conventional Chondrosarcoma.
How INBRX-109 works
All drug targets →- ChondrosarcomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314613, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for INBRX-109
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of INBRX-109
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933 · Ewing Sarcoma, Colorectal Adenocarcinoma
|
Phase 1 | Recruiting | Inhibrx Biosciences, Inc | UK, USA, France, Spain, Italy, Netherlands |
|
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075 · Conventional Chondrosarcoma
|
Phase 2 | Active, closed | Inhibrx Biosciences, Inc | Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with INBRX-109
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Inhibrx Biosciences, Inc | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about INBRX-109 trials
How many clinical trials are testing INBRX-109?
2 current trials in our UK, USA, France, Spain, Italy, Netherlands, Ireland, Germany and Australia registers name INBRX-109 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are INBRX-109 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors INBRX-109 clinical trials?
The lead sponsor is Inhibrx Biosciences, Inc. The number in brackets is how many trials each organisation leads.
Are there INBRX-109 clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how INBRX-109 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how INBRX-109 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists INBRX-109 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.